The global antiarrhythmic drugs market size is anticipated to reach USD 1.62 billion by 2030, growing at a CAGR of 6.4% from 2024 to 2030, according to a report by Grand View Research, Inc. This anticipated growth is driven by multiple interrelated factors, including the rising prevalence of cardiovascular diseases (CVDs), an aging global population, advancements in drug development, regulatory support, and government initiatives aimed at improving cardiovascular health. According to the World Health Organization (WHO), CVDs are the leading cause of death globally, responsible for approximately 17.9 million deaths annually.

Furthermore, the aging population is a significant factor contributing to market expansion. The U.S. Census Bureau reports that by 2030, approximately 20% of the U.S. population will be 65 years or older. This demographic shift is expected to lead to an increase in cardiovascular conditions, including arrhythmias, thereby heightening the demand for antiarrhythmic drugs. As people age, their risk of developing heart conditions increases, necessitating ongoing treatment and management strategies. This trend is not limited to the U.S.; many developed and developing nations are experiencing similar demographic changes, resulting in a global increase in demand for antiarrhythmic therapies.

Recent advancements in drug development are further propelling market growth. Research and innovation in the field of antiarrhythmic drugs have led to the introduction of novel compounds and therapeutic approaches. For instance, the development of new drug formulations that target specific ion channels has improved the efficacy and safety profiles of these medications. Moreover, advances in personalized medicine and pharmacogenomics are paving the way for tailored treatment strategies that optimize drug efficacy based on individual patient profiles. Such innovations not only enhance treatment outcomes but also encourage the adoption of antiarrhythmic therapies among healthcare providers.

Gather more insights about the market drivers, restrains and growth of the Antiarrhythmic Drugs Market

Antiarrhythmic Drugs Market Report Highlights

• By drug class, the beta blockers segment accounted for the largest revenue share of 34.7% in 2023. Their efficacy in reducing heart rate and controlling blood pressure has made them a cornerstone in the treatment of these disorders.

• Based on route of administration, the oral segment accounted for the largest revenue share of around 65.0% in 2023. Oral formulations allow patients to self-administer treatments at home, eliminating the need for invasive procedures or hospital visits, which can be particularly appealing in managing chronic conditions such as atrial fibrillation and ventricular tachycardia.   

• Based on distribution channels, the hospital pharmacies segment accounted for the largest revenue share of around 55.0% in global market for antiarrhythmic drugs in 2023.

Antiarrhythmic Drugs Market Segmentation

Grand View Research has segmented the global antiarrhythmic drugs market report based on drug class, route of administration, distribution channel, and region:

Antiarrhythmic Drug Class Outlook (Revenue, USD Million; 2018 - 2030)

• Sodium Channel Blockers

• Beta Blockers

• Potassium Channel Blockers

• Calcium Channel Blockers

• Other

Antiarrhythmic Route of Administration Outlook (Revenue, USD Million; 2018 - 2030)

• Oral

• Parenteral

• Other

Antiarrhythmic Distribution Channel Outlook (Revenue, USD Million; 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Other  

Antiarrhythmic Regional Outlook (Revenue, USD Million; 2018 - 2030) 

• North America

o U.S.

o Canada

o Mexico

• Europe

o Germany

o UK

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o China

o Japan

o India

o South Korea

o Australia

o Thailand

• Latin America

o Brazil

o Argentina

• Middle East and Africa (MEA)

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Order a free sample PDF of the Antiarrhythmic Drugs Market Intelligence Study, published by Grand View Research.